Investors are worried about the diabetes care technology leader's slowing growth.Shares of DexCom (DXCM -40.46%) were crashing 39.9% lower as of 10:20 a.m. ET on Friday. The huge sell-off came after the continuous glucose monitoring (CGM) systems maker announced its second-quarter results following the market close on Thursday.DexCom's revenue increased 15% year over year in Q2 to $1 billion. However, that came in a little below the average revenue estimate of $1.04 billion based on LSEG's survey of analyst ...

Dexcom (NASDAQ:DXCM) stock is down over 40% after reporting disappointing revenue for the second quarter.It also lowered guidance for the rest of the year.The problem lies with its Stelo continuous glucose monitor. The company is delaying the device’s launch as it builds inventory.Dexcom earned $143.5 million, 35 cents per share fully diluted, on revenue of $1 billion. But it guided toward slower growth, just 1% to 3% for the third quarter, and 11% to 13% for the year.DXCM stock opened this morning at about ...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...

SAN DIEGO, July 26, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether DexCom, Inc. (NASDAQ: DXCM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased DexCom securities? If you purchased securities and suffered losses on you ...

DexCom (NASDAQ:DXCM) stock is falling on Friday after the company released its earnings report for Q2 2024.DexCom starts its earnings report with adjusted earnings per share of 43 cents. That’s better than Wall Street’s estimate of 39 cents per share. It’s also an improvement over its adjusted EPS of 34 cents in the same period of the year prior.However, the company’s revenue of $1 billion failed to impress. It doesn’t stack up to analysts’ estimate of $1.04 billion. Even if its a 15% increase year-over-yea ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.Shares of DexCom, Inc. DXCM fell sharply during Friday's pre-market trading after the company reported worse-than-expected second-quarter revenue results and issued weak FY24 revenue guidance.DexCom reported quarterly earnings of 43 cents per share, which beat the analyst consensus estimate of 39 cents. Quarterly sales came in at $1.004 billion which missed the analyst consensus estimate of $1.036 billion.D ...

Core Viewpoint - DexCom reported disappointing Q2 earnings, missing estimates by 4% on the top end while slightly exceeding EPS expectations, indicating a puzzling slowdown in U.S. sales and anemic growth in international markets [2][3] Financial Performance - Q2 total revenues grew 15% year-over-year to approximately $1 billion, marking one of the worst quarterly sales growth performances in the last decade [3][4] - U.S. market revenue grew 19% year-over-year to $732 million, while international sales decelerated to 7% year-over-year, totaling $272 million [4][5] - Operating margin expanded by 1.3% to 19.5%, with net income increasing 24% to $143.5 million, or 35 cents per share, beating market expectations [7] Sales and Distribution Challenges - The company faced issues with sales through distribution channels, with distributor-originated sales growing 16% year-over-year to $860 million, accounting for 85% of total revenues [5] - Management cited ineffective relationships with DME distribution partners as a key issue impacting sales performance [5][11] - Increased pharmacy rebates due to faster-than-expected benefits coverage expansion also contributed to the sales slowdown [5] Outlook and Guidance - The company lowered its FY24 growth expectations, now projecting only 11% growth at the midpoint of its guidance range, down from previous projections [5][9] - Management anticipates Q3 sales to be between $975 million and $1 billion, significantly below market expectations of $1.15 billion [11] - DexCom's new product, Stelo, is expected to contribute approximately 1% to total revenues for FY24, but its impact may be diminished due to the overall downgraded outlook [11] Competitive Landscape - DexCom may be losing market share, as Abbott Labs reported a 20% sales growth in their competing Freestyle Libre CGM system, contrasting DexCom's outlook [6][9] Valuation and Future Expectations - The company's adjusted operating margins are now expected to expand by approximately 4%, down from earlier expectations of 6% [9] - DexCom's forward valuation multiple is estimated to be between 28-30x, suggesting a fair value of around $70 per share, which is 34% below its recent share price [10]

Key TakeawaysShares in Dexcom plunged in extended trading Thursday after the medical devices company posted second quarter results that came in below Wall Street expectations and slashed its annual revenue forecast.Dexcom shares look set to break down from a symmetrical triangle, a chart pattern that often precedes a trending move in the direction of the breakout.The Dexcom share price could attract buying interest at key chart levels including $70, $52, $37, and $24.On the four occasions the relative stren ...

DexCom, Inc. (NASDAQ:DXCM) Q2 2024 Earnings Conference Call July 25, 2024 4:30 PM ET Corporate Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Magaret Andrew - William Blair Travis Steed - Bank of America Matt Taylor - Jefferies Danielle Antalffy - UBS Joanne Wuensch - ...

DexCom (DXCM) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.26%. A quarter ago, it was expected that this medical device company would post earnings of $0.27 per share when it actually produced earnings of $0.32, delivering a surprise of 18.52%.Over the last four quarters, the co ...